BUZZ-Verona Pharma: Soars on positive data from mid-stage study
** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq (Frankfurt: 813516 - news) -listed companies
** Reports positive data from one mid-stage study of its treatment for cystic fibrosis, a disease that causes lung infections and limits the ability to breathe over time
** Patients in the trial treated with RPL554 showed statistically significant increase in average forced expiratory volume in one second;
** Stock has risen 38 pct in 2018 (Reporting by Mrinalini Krothapalli)